Literature DB >> 2653414

A meta-analysis of randomized control trials of progestational agents in pregnancy.

P Goldstein1, J Berrier, S Rosen, H S Sacks, T C Chalmers.   

Abstract

The continued use of progestational agents in attempts to achieve a normal outcome of pregnancy in women with a 'high-risk' pregnancy (previous miscarriage, stillbirth or present preterm labour) prompted this meta-analysis of randomized control trials of such therapy. Of 20 trials of a progestogen 15 had combinable data. Combined comparisons, using odds ratios with confidence intervals, were made of the rates of livebirths at term or preterm and the sum of term and preterm deliveries, miscarriages, stillbirths and neonatal deaths. All but one comparison failed to show a significant benefit. Only the preterm delivery versus the term delivery comparison approached statistical significance. There were average deficiencies of quality apparent in the studies, and a test for heterogeneity among the studies was positive, but these caveats do not diminish the conclusion that progestogens should not be used outside of randomized trials at present. If trials are done, they should include only women with demonstrated hormonal abnormalities who are carrying a live fetus as shown by ultrasonography.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2653414     DOI: 10.1111/j.1471-0528.1989.tb02385.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  12 in total

Review 1.  Progesterone treatment to prevent preterm birth.

Authors:  Paul J Meis; Alicia Aleman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  The management of preterm labour.

Authors:  Jayanta Chatterjee; Joanna Gullam; Manu Vatish; Steve Thornton
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-03       Impact factor: 5.747

Review 3.  Recurrent preterm birth.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Beth L Pineles; Francesca Gotsch; Pooja Mittal; Nandor Gabor Than; Jimmy Espinoza; Sonia S Hassan
Journal:  Semin Perinatol       Date:  2007-06       Impact factor: 3.300

4.  A national survey examining obstetrician perspectives on use of 17-alpha hydroxyprogesterone caproate post-US FDA approval.

Authors:  Andrei Rebarber; Nathan Fox; Chad K Klauser; Daniel Saltzman; Ashley S Roman
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

5.  Progestins Inhibit Tumor Necrosis Factor α-Induced Matrix Metalloproteinase 9 Activity via the Glucocorticoid Receptor in Primary Amnion Epithelial Cells.

Authors:  Terrence K Allen; Matthew N Nazzal; Liping Feng; Irina A Buhimschi; Amy P Murtha
Journal:  Reprod Sci       Date:  2018-11-19       Impact factor: 3.060

Review 6.  Bed rest during pregnancy for preventing miscarriage.

Authors:  A Aleman; F Althabe; J Belizán; E Bergel
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

7.  Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology.

Authors:  David M Haas; Taylor J Hathaway; Patrick S Ramsey
Journal:  Cochrane Database Syst Rev       Date:  2019-11-20

8.  Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro.

Authors:  Donal J Sexton; Michael W O'Reilly; Anne M Friel; John J Morrison
Journal:  Reprod Biol Endocrinol       Date:  2004-12-07       Impact factor: 5.211

9.  Progesterone supplementation in women with otherwise unexplained recurrent miscarriages.

Authors:  Munawar Hussain; Samawal El-Hakim; David J Cahill
Journal:  J Hum Reprod Sci       Date:  2012-09

10.  Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology.

Authors:  David M Haas; Taylor J Hathaway; Patrick S Ramsey
Journal:  Cochrane Database Syst Rev       Date:  2018-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.